
Early study finds new lymphoma drug effective
Eighty percent of patients with a subset of lymphoma saw their cancers shrink after taking zanubrutinib in a clinical trial.
Fischer promotes innovations in clinical care and tells patient stories on behalf of the Rogel Cancer Center while also managing external communications for Michigan Medicine’s surgery and urology departments and the Transplant Center. Before joining the university, she spent six years as a journalist. She has a passion for elevating translational research, highlighting the human element of science, and using a lens of diversity, equity and inclusion to shape her storytelling.
Eighty percent of patients with a subset of lymphoma saw their cancers shrink after taking zanubrutinib in a clinical trial.
Two surgeons-in-training suggest some sustainable solutions for their energy-intensive discipline.
After consulting with a machine learning tool, providers were able to more accurately determine whether patients had a complete response to chemotherapy.
Repaired hernias redeveloped more than 15% of the time in older Americans.
Providers quickly integrated systemic medications to treat high-risk melanoma into their care after clinical trial results showed their efficacy while simultaneously forgoing lymph node removal surgeries.
A multi-center study found that breast cancer patients experienced less pain and skin irritation when a more complex form of treatment planning was used for radiation.